Navigation Links
Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin ('PedPRM') to be Marketed by Biocodex in France
Date:3/13/2017

TEL AVIV, Israel, March 13, 2017 /PRNewswire/ --

Neurim Pharmaceuticals ('Neurim') announced today that it has entered into a licensing agreement with Biocodex. The agreement grants Biocodex exclusive marketing rights for Neurim's new Rx PedPRM in France.

Neurim's age-appropriate drug is targeted to treat sleep disorders in children with autism spectrum disorders (ASD) and neurogenetic diseases. It is expected to be the first sleep drug approved for children.

Biocodex promotes Circadin®, prolonged-release melatonin 2mg, indicated to treat primary insomnia in the elderly, since 2013 in France. "Biocodex played a significant role in obtaining reimbursement for Circadin under a Temporary Recommendation for Use (RTU) for treating sleep disorders in children with neurodevelopmental disorders. It was only natural that the collaboration will deepen to include PedPRM," said Sharon Elkobi, VP Business Development of Neurim Pharmaceuticals. "Additional agreements are expected to follow in order to make the new treatment accessible for children and their families."

"Sleep disturbances in children presenting with neurodevelopment disabilities represent an unresolved therapeutic challenge. In addition to Circadin® for the treatment of primary insomnia in adults, Biocodex is pleased to expand its productive partnership with Neurim and is proud to continue the work being done on the RTU in order to make this new promising product available for these children in France," said Paul Bernasconi, MD, Vice President France Operations of Biocodex.

About PedPRM 

PedPRM is a response to an unmet clinical need in the field of paediatric insomnia, specifically developed to address main concerns in children with ASD and neurogenetic diseases. PedPRM is an age-appropriate formulation designed for populations with swallowing difficulties.

PedPRM has recently completed a Phase III study, under EU-PIP and US-FDA IND, showing positive top-line results. The drug met the primary efficacy endpoint demonstrating statistically significant improvement in total sleep time (TST) compared to placebo. Secondary efficacy endpoints demonstrating improvements in sleep initiation and maintenance were met as well.

About Neurim Pharmaceuticals

Neurim Pharmaceuticals Ltd. (http://www.neurim.com) is a neuroscience drug discovery and development company. Its first approved drug Circadin® is commercially available in Europe, Asia-Pacific, Latin America, Africa and the Middle East.

The company has a strong and innovative product pipeline intended for insomnia, Alzheimer's disease, dementia, glaucoma and pain.

Contact:
Sharon Elkobi
VP Business Development
sharone@neurim.com


'/>"/>
SOURCE Neurim Pharmaceuticals Ltd.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Neurim Pharmaceuticals Grants Aspen Australia Marketing Rights for Paediatric Prolonged-Release Melatonin ("PedPRM") in Australia and New Zealand
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
4. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
5. Access Pharmaceuticals Reports First Quarter Results
6. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
7. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
8. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
9. Aveo Pharmaceuticals, Inc. Sued by Investor
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
11. Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2019)... ... 2019 , ... University Hospitals Urology Institute today announced that ... designation recognizes that Dr. Jaeger has achieved a high level of training and ... men suffering from symptoms associated with benign prostatic hyperplasia (BPH). , “I’m ...
(Date:1/8/2019)... ... January 08, 2019 , ... Date aired: August 13th, ... dry eye result from excessive evaporation of the tear film, which is naturally 99 ... in general. , So says water researcher Sharon Kleyne, host of the internationally syndicated ...
(Date:1/7/2019)... FRANCISCO (PRWEB) , ... January 07, 2019 , ... ... obstetrics, announced today that Philips, the leading international health technology company, has taken ... financing. Additional investors include StartUp Health and NueCura Partners. , Babyscripts has spent ...
Breaking Medicine Technology:
(Date:1/14/2019)... ... ... Early bird pricing for Medical Device Risk Management: Prepare for the Winds ... conflicted, confusing. And it is getting even more complicated , The international standard is ... new standard adds new definitions, changes the clause numbering, introduces new requirements, changes many ...
(Date:1/14/2019)... ... ... Presents All Reviewed & Approved Living Well Providers of 2019. , Acupuncture, ... Edward Izrailov - Maplewood , Dr. Joanna Jodar - Somerset , Dr. Barbara ... - Point Pleasant , Dr. Robert J. Reinhardt - Pequannock , Dr. Sylvester ...
(Date:1/13/2019)... (PRWEB) , ... January 12, 2019 , ... ... Professionals Committee (YPC) in conjunction with Temple University hosted a continuing education (CEU) ... and Mentees. The event aimed to create a series of talks to ...
(Date:1/11/2019)... ... January 11, 2019 , ... The ... in its “Next Generation Captive Insurance Solutions for New Risk Challenges” essay contest ... The three finalist teams are: , Christian Ferrara ...
(Date:1/10/2019)... ... January 10, 2019 , ... Mount Sinai Health ... Society at the United Nations Staff Recreation Council in support of the Helen ... complementary services including music, art, massage, and pet therapies to increase the comfort ...
Breaking Medicine News(10 mins):